Trastuzumab (Herceptin) Therapy
~ Dr. Yang Liu
Trastuzumab (Herceptin) was originally approved for the use of Her2/neu positive breast cancers. However, studies demonstrated that Her2/neu is overexpressed in as many as 20% of all gastric adenocarcinomas. According to the report of a large phase III trial called the ToGA trial, Trastuzumab (Herceptin) in combination with traditional chemotherapy showed significant benefits on Her2/neu positive advanced gastric/gastro-esophageal cancers. At A&P, we routinely test Her2/neu on every breast cancer patient and every patient with advanced gastric/gastro-esophageal adenocarcinoma.